Waldo Ortuzar

966 total citations · 1 hit paper
10 papers, 756 citations indexed

About

Waldo Ortuzar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Waldo Ortuzar has authored 10 papers receiving a total of 756 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Waldo Ortuzar's work include Cancer Immunotherapy and Biomarkers (4 papers), CAR-T cell therapy research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Waldo Ortuzar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), CAR-T cell therapy research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Waldo Ortuzar collaborates with scholars based in United States, Chile and Italy. Waldo Ortuzar's co-authors include Tito Fojo, K Paull, Manuel Álvarez, R. R. Parker, Eddie Reed, Olivier Rixe, Ralph Zinner, John N. Weinstein, Timothy G. Myers and Hideyuki Tanimura and has published in prestigious journals such as Annals of Oncology, Biochemical Pharmacology and BMC Cancer.

In The Last Decade

Waldo Ortuzar

10 papers receiving 738 citations

Hit Papers

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spe... 1996 2026 2006 2016 1996 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
    1996 510 citations Olivier Rixe, Waldo Ortuzar et al. Biochemical Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Waldo Ortuzar United States 7 574 229 203 112 84 10 756
Jianguo Ma China 18 359 0.6× 487 2.1× 131 0.6× 72 0.6× 69 0.8× 49 879
A.L. Jackman United Kingdom 13 513 0.9× 503 2.2× 150 0.7× 100 0.9× 75 0.9× 24 842
Axel R. Hanauske Germany 11 425 0.7× 426 1.9× 490 2.4× 95 0.8× 88 1.0× 19 1.0k
Ben Allal France 20 347 0.6× 489 2.1× 132 0.7× 44 0.4× 52 0.6× 32 918
Alberto D’Angelo United Kingdom 18 449 0.8× 348 1.5× 382 1.9× 40 0.4× 98 1.2× 59 1000
Grant A. Williams United States 9 707 1.2× 450 2.0× 588 2.9× 153 1.4× 72 0.9× 9 1.3k
Giuseppe Viscardi Italy 15 400 0.7× 288 1.3× 264 1.3× 37 0.3× 49 0.6× 46 871
Nicola Dobbs United Kingdom 15 378 0.7× 367 1.6× 95 0.5× 118 1.1× 65 0.8× 26 899
A.-R. Hanauske Germany 14 341 0.6× 308 1.3× 214 1.1× 81 0.7× 28 0.3× 43 702
Jai Balkissoon United States 14 252 0.4× 314 1.4× 112 0.6× 186 1.7× 60 0.7× 20 757

Countries citing papers authored by Waldo Ortuzar

Since Specialization
Citations

This map shows the geographic impact of Waldo Ortuzar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Waldo Ortuzar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Waldo Ortuzar more than expected).

Fields of papers citing papers by Waldo Ortuzar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Waldo Ortuzar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Waldo Ortuzar. The network helps show where Waldo Ortuzar may publish in the future.

Co-authorship network of co-authors of Waldo Ortuzar

This figure shows the co-authorship network connecting the top 25 collaborators of Waldo Ortuzar. A scholar is included among the top collaborators of Waldo Ortuzar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Waldo Ortuzar. Waldo Ortuzar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
O’Day, Steven, Chethan Ramamurthy, Andrea J. Bullock, et al.. (2020). 398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. Regular and Young Investigator Award Abstracts. A242.1–A242. 2 indexed citations
2.
Wilky, Breelyn A., Priya Kumthekar, Robert Wesolowski, et al.. (2018). Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy. Annals of Oncology. 29. viii416–viii417. 2 indexed citations
3.
4.
Coward, Jermaine, Charlotte Lemech, Tarek Meniawy, et al.. (2018). Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors. Annals of Oncology. 29. viii417–viii417. 3 indexed citations
5.
6.
Ortuzar, Waldo, Nasser H. Hanna, Eduardo J. Pennella, et al.. (2011). Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(1). 24–30. 24 indexed citations
7.
8.
González‐Hormazábal, Patricio, Rafael Blanco, Carlos Y Valenzuela, et al.. (2008). Association of common ATMvariants with familial breast cancer in a South American population. BMC Cancer. 8(1). 117–117. 32 indexed citations
9.
10.
Rixe, Olivier, Waldo Ortuzar, Manuel Álvarez, et al.. (1996). Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel. Biochemical Pharmacology. 52(12). 1855–1865. 510 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianguo Ma Breakdown of academic impact, for papers by A.L. Jackman Breakdown of academic impact, for papers by Axel R. Hanauske Breakdown of academic impact, for papers by Ben Allal Breakdown of academic impact, for papers by Alberto D’Angelo Breakdown of academic impact, for papers by Grant A. Williams Breakdown of academic impact, for papers by Giuseppe Viscardi Breakdown of academic impact, for papers by Nicola Dobbs Breakdown of academic impact, for papers by A.-R. Hanauske Breakdown of academic impact, for papers by Jai Balkissoon
Rankless by CCL
2026